louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05495880: Forearm-Supported Head Extension to Decrease Dental Contact
Official title: Forearm-Supported Head Extension to Decrease Dental Contact Between Laryngoscope Blade and Maxillary Incisors During Direct Laryngoscopy
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Endotracheal Intubation
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2022-08-10
Enrollment: 84
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to determine whether the forearm-supported head extension decreases dental contact between laryngoscope blade and maxillary incisors during direct laryngoscopy


Eligibility criteria: Inclusion Criteria:

* Patients undergoing surgery that require endotracheal intubation for general anesthesia

Exclusion Criteria:

* Trauma or disease or cervical spine
* Toothless patient
* Dentoalveolar injury
* Anatomical anomaly of face or airway
* History of difficult intubation
* Patient refusal

Primary outcomes:
measure: Dental contact
timeFrame: during laryngoscopy
Secondary outcomes:
measure: Blade-to-tooth distance
timeFrame: during laryngoscopy
measure: Angle of head extension
timeFrame: during laryngoscopy
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00583180: Sensory Function After Wound Instillation of Capsaicin
Official title: Cutaneous Sensory Function After Wound Instillation of Capsaicin During Groin Hernia Repair
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Primary Hyperalgesia
Keywords: Primary and/or secondary hyperalgesia
hypoesthesia
Lead sponsor: Rigshospitalet, Denmark
Sponsor class: OTHER
First posted: 2007-12-31
Enrollment: 42
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult males with primary unilateral groin hernia

Brief summary: The use of capsaicin as a potential analgesic drug for postoperative pain relies on the ability of capsaicin to induce membrane lysis of c-nerve fibers. In a previous randomized placebo controled blinded study of this effect we found a significant effect of capsaicin versus placebo. Before surgery all patients were examined by quantitative sensory testing to evaluate sensory function. In this study an identical sensory testing will examine if changes to the sensory function in capsaicin treated patients is identical to placebo treated patients.No new intervention will be performed


Eligibility criteria: Inclusion Criteria:

* Primary groin hernia planned to undergo Lichtenstein mesh repair
* Ability to use pain scales
* American Society of Anesthesiologist class I or II based upon medical history, physical examination, and screening laboratory results
* Willing to take oral pain medication (acetaminophen, ibuprofen) for the first week
* Willing to fill out a diary for four weeks following surgery.

Exclusion Criteria:

* A previous lower abdominal surgical procedure
* Bupivacaine, acetaminophen, ibuprofen, or tramadol
* A medical condition likely to alter wound healing or pain ratings
* Systolic blood pressure greater than 150 or diastolic greater than 95 mm Hg
* Contraindication to general anesthesia
* Bilateral hernia repair
* A history of drug or alcohol abuse within the past two years
* Use of antihypertensive, antidepressant, or psychotropic drug that has not been stable for 3 months
* Use of an investigational drug within 3 months or scheduled to receive an investigational drug other than ALGRX 4975 during the study period.

Primary outcomes:
measure: changes in sensory function before and 2 years after groin hernia repair in patients with and without capsaicin instillation, evaluated by quantitative sensory testing
timeFrame: 2 years
Secondary outcomes:
measure: Frequency of chronic pain
timeFrame: 2 years
Other outcomes:
Locations:
city: Hørsholm
country: Denmark
facility: Hørshol Sygehus
Study officials:
affiliation: Rigshospitalet, Denmark
name: Henrik Kehlet, M.D, Ph. D.
role: STUDY_DIRECTOR
References:
Clinical trial NCT02166580: Accuracy of CNAP PPV Under General Anaesthesia
Official title: Comparison of the Non-invasive CNAP Pulse Pressure Variation With the Invasive Gold Standard
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: General Anaesthesia
Lead sponsor: University Hospital Schleswig-Holstein
Sponsor class: OTHER
First posted: 2014-06-18
Enrollment: 54
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients undergoing major surgery with the need for invasive arterial pressure monitoring

Brief summary: Noninvasive pulse pressure variation for the guidance of perioperative fluid therapy is compared with the gold standard of invasive measurements. Cardiac output is derived by the PICCO monitor.

Hypothesis: Noninvasive CNAP PPV predicts fluid responsiveness. A grey zone for the prediction of fluid responsiveness will be defined.

Detailed description: Accuracy of PPV measured by two devices,PICCO and CNAP, is compared with the manually calculated PPV from the arterial line waveform. Established tests like passive leg raising and end-expiratory occlusion are used for prediction of fluid responsiveness. Intraoperative events like volume challenge are monitored.

Eligibility criteria: Inclusion Criteria:

* major surgery
* need for invasive arterial measurements

Exclusion Criteria:

* age under 18
* cardiac dysrhythmia
* vascular pathology at punction site

Primary outcomes:
measure: Cardiac output
timeFrame: 1, 2, 5, 10, 15 and 20 minutes after volume challange and
Secondary outcomes:
Other outcomes:
Locations:
city: Kiel
country: Germany
facility: University Hospital, Schleswig-Holstein. Departement of Anaesthesiology and Intensive Care Medicine
Study officials:
affiliation: University Hospital Schleswig-Holstein, Departement of Anaesthesia and Intensive Care Medicine
name: Jochen Renner, PD Dr.
role: PRINCIPAL_INVESTIGATOR
affiliation: University Hospital Schleswig-Holstein, Departement of Anaesthesia and Intensive Care Medicine
name: Robert Hanss, Prof. Dr.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Renner J, Gruenewald M, Hill M, Mangelsdorff L, Aselmann H, Ilies C, Steinfath M, Broch O. Non-invasive assessment of fluid responsiveness using CNAP technology is interchangeable with invasive arterial measurements during major open abdominal surgery. Br J Anaesth. 2017 Jan;118(1):58-67. doi: 10.1093/bja/aew399.
Clinical trial NCT00540280: Randomized Phase III Trial of Surgery Alone or Surgery Plus Preoperative Gemcitabine-Cisplatin in Clinical Early Stages of Non-small Cell Lung Cancer
Study type: INTERVENTIONAL
Overall status: SUSPENDED
Phase: PHASE3
Conditions: Carcinoma, Non-Small-Cell Lung
Keywords: NSCLC
Lead sponsor: King Faisal Specialist Hospital & Research Center
Sponsor class: OTHER
First posted: 2007-10-05
Enrollment: 10
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Randomized Phase III trial of surgery alone or surgery plus preoperative Gemcitabine-Cisplatin in clinical early stages of non-small cell lung cancer


Eligibility criteria: Inclusion Criteria:

* Patients with early stage NSCLC

Primary outcomes:
measure: OS, MS, DFS
timeFrame: overall
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: King Faisal Specialist Hospital & Research Centre, Saudi Arabia
name: Khalid Rehman, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04249180: Eye Rubbing and Keratoconus in Montpellier CHU
Official title: Assessment of the Lived Experience of the Disease of the Patients Followed at the CHU of Gui de Chauliac for a Keratoconus and Their Habit of Eye Rubbing
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Keratoconus
Keywords: primitive corneal ectasia
Ophthalmology
Eyes rubbing
Keratoconus
Lead sponsor: University Hospital, Montpellier
Sponsor class: OTHER
First posted: 2020-01-30
Enrollment: 0
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patient is having a keratoconus in at least one eye. It is a deases with a primitive corneal ectasia.

Brief summary: Evaluate the illness experience of patients with keratoconus as well as the rubbing habits of this population compared to the general population. To do this, the investigators used a questionnaire made by a Bordeaux team with questions on the experience of the patients' illness, their management and their friction habits


Eligibility criteria: Inclusion criteria:

- Having a keratonus at least in one eyes

Exclusion criteria:

- Refus to participate

Primary outcomes:
measure: Assess whether eye rubbing is a risk factor for keratoconus
timeFrame: 1 day
Secondary outcomes:
measure: Evaluate the habits of the population with a keratoconus
timeFrame: 1 day
Other outcomes:
Locations:
city: Montpellier
country: France
facility: UH Montpellier
Study officials:
affiliation: University Hospitals of Montpellier
name: Gabriel Planells, Internship of ophthalmology
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01953380: Intervention Study to Evaluate the Importance of Information Given to Patients With Contact Allergy
Official title: Intervention Study to Evaluate the Importance of Information Given to Patients With Contact Allergy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Dermatitis, Allergic Contact
Keywords: Intervention Studies
Eczema
Randomized Controlled Trial
Knowledge
Quality of Life
Lead sponsor: Region Skane
Sponsor class: OTHER
First posted: 2013-10-01
Enrollment: 400
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to determine whether extended information given to patients with contact allergy improves knowledge, treatment efficacy and daily functioning.


Eligibility criteria: Inclusion Criteria:

* Patients with suspected contact allergy
* Age above 18 years
* Participants have given informed consent

Exclusion Criteria:

* Mental or language disabilities

Primary outcomes:
measure: knowledge
timeFrame: one year after inclusion
Secondary outcomes:
measure: clinical improvement
timeFrame: one year after inclusion
measure: quality of life
timeFrame: one year after inclusion
measure: effect on daily functioning
timeFrame: one year after inclusion
Other outcomes:
Locations:
city: Lund
country: Sweden
facility: Hudmottagningen SUS
state: Skåne
Study officials:
affiliation: Region Skåne, Hudkliniken SUS
name: Andreas Sonesson, MD PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Mossing K, Dizdarevic A, Svensson A, Sonesson A. Impact on quality of life of an intervention providing additional information to patients with allergic contact dermatitis; a randomized clinical trial. J Eur Acad Dermatol Venereol. 2022 Nov;36(11):2166-2171. doi: 10.1111/jdv.18412. Epub 2022 Jul 18.
Clinical trial NCT03192280: Skin IaM: An Exploratory Clinical Trial to Evaluate Changes in Skin Appearance, Colour, and/or Texture Following the Induction of a Local Inflammatory Skin Response
Official title: Skin IaM: An Exploratory Clinical Trial to Evaluate Changes in Skin Appearance, Colour, and/or Texture Following the Induction of a Local Inflammatory Skin Response
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Skin Inflammation
Lead sponsor: LEO Pharma
Sponsor class: INDUSTRY
First posted: 2017-06-20
Enrollment: 12
Sex: MALE
Minimum age (years): 25
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: This trial will test the feasibility of various imaging devices to detect local skin inflammation prior to clinical manifestation.


Eligibility criteria: Inclusion Criteria:

* Male aged \>25- \<40 years.
* Healthy, non-smoker.
* In the opinion of the investigator, the subject will be able to comply with the requirements of the protocol, including ability to present for all required visits.
* Subject is capable of understanding and signing an informed consent form.
* White origin (limit Skin Fitzpatrick I to III).

Exclusion Criteria:

* Male aged \< 25 years or \>40 years.
* Female of any age.
* Tattoos on or within 5 cm of the area to be assessed.
* Scars on or with 5 cm of the area to be assessed.
* Current, active inflammatory skin disease, or past history of any inflammatory skin disease (other than acne) such as psoriasis, atopic dermatitis.
* Suffered from any significant allergies (i.e. food, environmental, contact).
* Subjects who are immunocompromised (i.e. HIV positive, Hepatitis C, transplant, etc.), based on clinical history.
* Subjects who currently have an activated immune system (e.g from current infection or recent vaccination).
* Subjects who have a history of chronic disease such as diabetes.
* Use of investigational therapy in the preceding month prior to screening visit.
* Use of G-CSF, GM-CSF, IL-2, IFNs, erythropoietin, systemic or inhaled steroids within one month of the screening visit.
* Use of oral analgesics/anti-inflammatories (e.g. paracetamol, ibuprofen, aspirin, codeine) or topical anti-inflammatories (e.g., ibuprofen) within 5 days of the screening visit.
* Concurrent disease or conditions that may present a risk to the subjects.

Primary outcomes:
measure: Time-point of change from baseline and comparator in electro-magnetic spectra as measured by HSI PARC
timeFrame: Day 1 to Day 3
Secondary outcomes:
Other outcomes:
Locations:
city: Herston
country: Australia
facility: Investigational Site
Study officials:
affiliation: Q-Pharm Pty Limited
name: Paul Griffin, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03155880: Obesity Heterogeneity Study
Official title: National Health and Nutrition Examination Survey (NHANES), Obesity Heterogeneity Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Obesity
Lead sponsor: Unity Health Toronto
Sponsor class: OTHER
First posted: 2017-05-16
Enrollment: 1685
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: The analyses presented in this report included obese adult participants \>=20 years of age, giving a sample size of 1,873 (90% of obese participants). Due to missing data in the covariates, the final analytical sample size was 1,685 (90 % of intended sample).

Brief summary: The investigators will assess the heterogeneity of obese individuals in the United States to help researchers, clinicians and policymakers to establish goals for obesity treatment and identify whether differing interventions may be needed.

Detailed description: Guidelines for obesity set common targets for interventions and goals around weight loss, and randomized trials and epidemiologic studies of obesity tend to consider obesity to be a homogeneous entity . The investigators will analyze data from the 2011-2012 wave of the NHANES. Obesity will be defined as having a body mass index greater than or equal to 30 Kg/m2. The investigators aim to identify obese sub-groups according to demographic factors, clinical conditions and behavioral characteristics. Results of this type of analysis will shed light on an important gap in the way that obesity interventions and guidelines are developed and will be an important step in beginning the discussion towards this important area.

Eligibility criteria: Inclusion Criteria:

* All

Exclusion Criteria:

* Pregnant

Primary outcomes:
measure: Obesity
timeFrame: One day. The body measures data were collected, in the Mobile Examination Center (MEC), by trained health technicians.
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01597180: Pharmacokinetics, Pharmacodynamics and Cervicovaginal Lavage of Combined Oral Contraceptives and Raltegravir
Official title: Pharmacokinetics, Pharmacodynamics and Genital Tract Viral Shedding in HIV+ Women Using Combined Oral Contraceptives and Raltegravir
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: HIV
Keywords: contraception
HIV
pharmacokinetics
pharmacodynamics
Lead sponsor: University of North Carolina, Chapel Hill
Sponsor class: OTHER
Collaborators: name: Merck Sharp & Dohme LLC
First posted: 2012-05-11
Enrollment: 0
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Women recruited from an infectious diseases clinic in Chapel Hill, NC.

Brief summary: The purpose of this trial is to learn about potential interactions between raltegravir and a birth control pill in HIV+ women. The investigators plan to enroll HIV+ women who are on steady state raltegravir containing highly active antiretroviral therapy (HAART), ages 20-40, inclusive, who report regular monthly menses.

The investigators will investigate drug interactions of raltegravir, ethinyl estradiol (EE) and levonorgestrel (LNG). All women will be receiving raltegravir as part of their regular medical care. Women will be enrolled in the study for approximately 8 months.


Eligibility criteria: Inclusion Criteria:

* Women between 20-40 years of age with regular monthly menses
* If over age 35 then must not use tobacco
* Negative pregnancy test
* No known allergy to raltegravir
* No known history of phenylketonuria
* Undetectable HIV viral load
* No active liver disease as determined by medical history and normal AST and ALT
* No history of hepatic adenomas, carcinomas or benign liver tumors
* Ho history of thrombophlebitis of thromboembolic disease
* No history of deep vein thrombosis
* No history of cerebral vascular or coronary artery disease
* No known or suspected carcinoma of the breast
* No undiagnosed abnormal genital bleeding
* Not taking concomitant CYP 450 inducing medications such as anti-seizure medications
* No use of oral contraceptives, depot-medroxyprogesterone acetate, contraceptive ring or patch within two months of screening
* No cholestatic jaundice of pregnancy or jaundice with prior contraceptive pill use
* Has used raltegravir prior to screening
* Has no history of malignancy of the genital tract (e.g. cervical cancer, ovarian cancer, endometrial cancer)
* Must not have had an abnormal pap test defined without resolution in the last 18 months.

Primary outcomes:
measure: Change in cervicovaginal fluide milieu
Secondary outcomes:
Other outcomes:
Locations:
city: Chapel Hill
country: United States
facility: UNC Infectious Disease Clinic
state: North Carolina
Study officials:
affiliation: University of North Carolina, Chapel Hill
name: Gretchen S Stuart, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01471080: A Prospective Controlled Study on Treatment of Giant Cavernous Hemangiomas of the Liver
Official title: A Prospective Controlled Study on Treatment of Giant Cavernous Hemangiomas of the Liver：RFA Versus Laparoscopic Hepatectomy.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Laparoscopic Hepatectomy
Radio-frequency Ablation
Giant Cavernous Hemangiomas
Liver
Keywords: laparoscopic hepatectomy
radio-frequency ablation
giant cavernous hemangiomas
liver
Lead sponsor: Southwest Hospital, China
Sponsor class: OTHER
First posted: 2011-11-11
Enrollment: 140
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: In the past, the investigators often treated giant cavernous hemangiomas of the liver by hepatectomy.Recently RFA and laparoscopic hepatectomy are also available and could be applied to cure this disease.But we can't get a clear answer about their effectiveness and safety. Hence the investigators conduct this study to explore the effectiveness and efficiency of the these two methods and compare their short to mid-term outcomes.


Eligibility criteria: Inclusion Criteria:

* giant cavernous hemangiomas with a diameter larger than or equal to 5 cm diagnosed by more than one imaging modalities
* age between 18 years to 65 years
* without gender restriction
* PLT account more than 50 e9
* without abnormal of liver function test
* with substantial evidence of growing size than before
* symptom associated cavernous hemangiomas
* with a strong desire of the patients for the treatment

Exclusion Criteria:

* pregnant women
* abnormal of liver function or coagulation dysfunction and/or concurrent with sever cardiac or pulmonary disorders
* patient with a poor condition that can't bear the approach of either RFA or laparoscopic hepatectomy
* tumor size more than 20cm

Primary outcomes:
measure: disappearance rate of disease
timeFrame: 1 month
Secondary outcomes:
measure: complication rate
timeFrame: 1 month
measure: hospital stay and relating overall cost for treatment
timeFrame: 1 month
Other outcomes:
Locations:
city: Chongqing
country: China
facility: Institute of hepatobiliary surgery,southwest hospital
state: Chongqing
Study officials:
References:
Clinical trial NCT04951180: Arthroscopic Treatment for Femoral Acetabular Impingement Syndrome With Gluteus Medius Lesions.
Official title: Arthroscopic Treatment for Femoral Acetabular Impingement Syndrome With Gluteus Medius Lesions.
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Femoral Acetabular Impingement
Lead sponsor: Peking University Third Hospital
Sponsor class: OTHER
First posted: 2021-07-06
Enrollment: 150
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Femoral acetabular impingement syndrome (FAIS) patients with gluteus medius lesions.

Brief summary: To evaluate the prognosis of femoral acetabular impingement syndrome (FAIS) patients with gluteus medius lesions after hip arthroscopy.

Detailed description: The data of FAIS patients with gluteus medius lesions were retrospectively extracted pre- and postoperatively after hip arthroscopy. The prognosis of the surgery was evaluated through MRI images.

Eligibility criteria: Inclusion Criteria

* Diagnosed FAIS
* Ineffective conservative treatment
* Available pre- and postoperative images

Exclusion Criteria

* Revision arthroscopy
* Osteoarthritis
* History of hip joint disease or surgery
* Sacroiliac joint disease
* Loss of follow-up

Primary outcomes:
measure: MRI images
timeFrame: at least 1-year after hip arthroscopy
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Peking University Third Hospital
Study officials:
affiliation: Peking University Third Hospital
name: Jian-quan Wang, M.D.
role: STUDY_CHAIR
References: